MSTN and pulmonary arterial hypertension: Although the contribution of elevated GDF8/myostatin to the pathogenesis of PAH is less clear, blockade of GDF8/myostatin may provide benefit to patients to counter the reduced skeletal muscle mass and weakness reported in IPAH patients.124